KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Regeneron Pharmaceuticals (REGN) Other Non-Current Liabilities (2016 - 2025)

Regeneron Pharmaceuticals has reported Other Non-Current Liabilities over the past 17 years, most recently at $2.0 billion for Q4 2025.

  • Quarterly results put Other Non-Current Liabilities at $2.0 billion for Q4 2025, up 28.47% from a year ago — trailing twelve months through Dec 2025 was $2.0 billion (up 28.47% YoY), and the annual figure for FY2025 was $2.0 billion, up 28.47%.
  • Other Non-Current Liabilities for Q4 2025 was $2.0 billion at Regeneron Pharmaceuticals, up from $1.9 billion in the prior quarter.
  • Over the last five years, Other Non-Current Liabilities for REGN hit a ceiling of $2.0 billion in Q4 2025 and a floor of $43.7 million in Q3 2023.
  • Median Other Non-Current Liabilities over the past 5 years was $720.8 million (2022), compared with a mean of $1.0 billion.
  • Biggest five-year swings in Other Non-Current Liabilities: crashed 92.7% in 2023 and later soared 3432.27% in 2024.
  • Regeneron Pharmaceuticals' Other Non-Current Liabilities stood at $680.2 million in 2021, then fell by 6.2% to $638.0 million in 2022, then surged by 33.87% to $854.1 million in 2023, then surged by 83.98% to $1.6 billion in 2024, then increased by 28.47% to $2.0 billion in 2025.
  • The last three reported values for Other Non-Current Liabilities were $2.0 billion (Q4 2025), $1.9 billion (Q3 2025), and $1.7 billion (Q2 2025) per Business Quant data.